The JCOG1019 trial compared active surveillance and intravesical bacillus Calmette-Guérin (BCG) in patients with high-grade T1 bladder cancer at initial transurethral resection of the bladder (TURB) and no residual tumor at second TURB. Active surveillance was noninferior to intravesical BCG in terms of survival free from cystectomy, muscle-invasive disease, metastasis, and death.
The JCOG1019 trial compared active surveillance and intravesical bacillus Calmette-Guérin (BCG) in patients with high-grade T1 bladder cancer at initial transurethral resection of the bladder (TURB) and no residual tumor at second TURB. Active surveillance was noninferior to intravesical BCG in terms of survival free from cystectomy, muscle-invasive disease, metastasis, and death.